Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: A Southwest Oncology Group Study (SWOG 9235)
Autore:
Kucuk, O; Fisher, E; Moinpour, CM; Coleman, D; Hussain, MHA; Sartor, AO; Chatta, GS; Lowe, BA; Eisenberger, MA; Crawford, ED;
Indirizzi:
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA Wayne State Univ Detroit MI USA niv, Karmanos Canc Inst, Detroit, MI USA Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA Fred Hutchinson Canc Res Ctr Seattle WA USA 98104 , Seattle, WA 98104 USA Canc Res Ctr Hawaii, Honolulu, HI 96813 USA Canc Res Ctr Hawaii Honolulu HI USA 96813 Hawaii, Honolulu, HI 96813 USA Louisiana State Univ, Med Ctr, New Orleans, LA USA Louisiana State Univ New Orleans LA USA iv, Med Ctr, New Orleans, LA USA Univ Arkansas Med Sci, Little Rock, AR 72205 USA Univ Arkansas Med Sci Little Rock AR USA 72205 Little Rock, AR 72205 USA Oregon Hlth Sci Univ, Portland, OR 97201 USA Oregon Hlth Sci Univ Portland OR USA 97201 i Univ, Portland, OR 97201 USA Johns Hopkins Univ, Baltimore, MD USA Johns Hopkins Univ Baltimore MD USA ohns Hopkins Univ, Baltimore, MD USA Univ Colorado, Denver, CO 80202 USA Univ Colorado Denver CO USA 80202Univ Colorado, Denver, CO 80202 USA
Titolo Testata:
UROLOGY
fascicolo: 1, volume: 58, anno: 2001,
pagine: 53 - 58
SICI:
0090-4295(200107)58:1<53:PITOBI>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
PALLIATIVE END-POINTS; LOW-DOSE PREDNISONE; MITOXANTRONE; HISTORY; DISEASE; LIFE; PAIN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Kucuk, O SW Oncol Grp, Operat Off, SWOG-9235,14980 Omicron Dr, San Antonio, TX 78245 USA SW Oncol Grp SWOG-9235,14980 Omicron Dr San Antonio TX USA 78245
Citazione:
O. Kucuk et al., "Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: A Southwest Oncology Group Study (SWOG 9235)", UROLOGY, 58(1), 2001, pp. 53-58

Abstract

Objectives. To determine the efficacy and tolerability of bicalutamide in patients with advanced prostate cancer with progression after conventional hormonal therapy. Methods. Fifty-two patients received bicalutamide, 150 mg once daily, as second-line therapy after progressing following treatment with orchiectomy or luteinizing hormone-releasing hormone analogue or diethylstilbestrol, alone or in combination. Patients had measurable (n = 8) or assessable (n = 44) disease, a Southwest Oncology Group performance status of 0 to 2, and no prior antiandrogen therapy or chemotherapy. The objective response to treatment was assessed every 12 weeks; symptoms and pain were assessed monthly with questionnaires for 6 months. Results. There was evidence of palliation with three measures of pain and,to a lesser extent, with a measure of overall symptom status after 3 months of taking bicalutamide. No complete or partial responses occurred. However, 9 (20%) of 44 subjects with adequate prostate-specific antigen data had a 50% or higher decrease in their prostate-specific antigen levels, which did not correlate with symptom improvement. The median survival time was 15 months. The most common side effects were hot flashes (23%) and nausea (21%). Conclusions. These data suggest that bicalutamide decreases pain and improves symptom status in patients with prostate cancer in whom first-line hormonal therapy failed. UROLOGY 58: 53-58, 2001. ( C) 2001, Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 18:06:08